SILO PHARMA, INC. Cash and Restricted Cash
SILO PHARMA, INC. (SILO) had Cash and Restricted Cash of $3.28 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.28M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.90M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.75M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.92M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $3.28M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $3.90M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $4.75M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $3.92M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $4.33M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $3.14M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $3.91M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $4.86M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $4.51M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $2.67M 10-Q · filed 2025-05-09 |
| 2023-12-31 | $3.52M POS AM · filed 2026-04-14 |
| 2023-09-30 | $199.84K 10-Q · filed 2024-11-12 |
| 2023-06-30 | $158.83K 10-Q · filed 2024-08-13 |
| 2023-03-31 | $4.67M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $11.37M 10-K · filed 2025-03-28 |
| 2022-09-30 | $12.25M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $8.73M 10-Q · filed 2023-08-11 |
| 2022-03-31 | $9.07M 10-Q · filed 2023-05-12 |
| 2021-12-31 | $9.84M 10-K · filed 2024-03-25 |
| 2021-09-30 | $10.26M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $4.15M 10-Q · filed 2022-08-01 |
| 2021-03-31 | $4.64M 10-Q · filed 2022-05-13 |
| 2020-12-31 | $1.13M 10-K · filed 2023-03-24 |
| 2019-12-31 | $111.75K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |